<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVES: Photodynamic therapy (<z:chebi fb="7" ids="53228">PDT</z:chebi>) with porfimer <z:chebi fb="199" ids="26708">sodium</z:chebi>, FDA approved to treat <z:e sem="disease" ids="C0850639" disease_type="Neoplastic Process" abbrv="">premalignant lesions</z:e> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, causes <z:hpo ids='HP_0000992'>photosensitivity</z:hpo> for 6-8 weeks </plain></SENT>
<SENT sid="1" pm="."><plain>HPPH (2-[1-hexyloxyethyl]-2-devinyl <z:chebi fb="0" ids="48398">pyropheophorbide-a</z:chebi>) shows minimal <z:e sem="disease" ids="C0031763" disease_type="Disease or Syndrome" abbrv="">photosensitization</z:e> of short duration and promising efficacy in preclinical studies </plain></SENT>
<SENT sid="2" pm="."><plain>Here we explore toxicity and optimal drug and light dose with endoscopic HPPH-<z:chebi fb="7" ids="53228">PDT</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>We also want to know the efficacy of one time treatment with HPPH-<z:chebi fb="7" ids="53228">PDT</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>STUDY DESIGN/MATERIALS AND METHODS: Two nonrandomized dose escalation studies were performed (18 patients each) with biopsy-proven high grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or early intramucosal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> of esophagus </plain></SENT>
<SENT sid="5" pm="."><plain>HPPH doses ranged from 3 to 6 mg/m2  </plain></SENT>
<SENT sid="6" pm="."><plain>At 24 or 48 hours after HPPH administration the lesions received one endoscopic exposure to 150, 175, or 200 J/cm of 665 nm light </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Most patients experienced mild to moderate <z:hpo ids='HP_0100749'>chest pain</z:hpo> requiring symptomatic treatment only </plain></SENT>
<SENT sid="8" pm="."><plain>Six patients experienced grade 3 and 4 adverse events (16.6%) </plain></SENT>
<SENT sid="9" pm="."><plain>Three <z:hpo ids='HP_0002043'>esophageal strictures</z:hpo> were treated with <z:mpath ids='MPATH_66'>dilatation</z:mpath> </plain></SENT>
<SENT sid="10" pm="."><plain>No clear pattern of dose dependence of toxicities emerged </plain></SENT>
<SENT sid="11" pm="."><plain>In the drug dose ranging study (light dose of 150 J/cm at 48 hours), 3 and 4 mg/m2 of HPPH emerged as most effective </plain></SENT>
<SENT sid="12" pm="."><plain>In the light dose ranging study (3 or 4 mg/m2 HPPH, light at 24 hours), complete response rates (disappearance of high grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and early <z:mp ids='MP_0002038'>carcinoma</z:mp>) of 72% were achieved at 1 year, with <z:hpo ids='HP_0000001'>all</z:hpo> patients treated with 3 mg/m2 HPPH plus 175 J/cm and 4 mg/m2 HPPH plus 150 J/cm showing complete responses at 1 year </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: HPPH-<z:chebi fb="7" ids="53228">PDT</z:chebi> for <z:e sem="disease" ids="C0940937" disease_type="Neoplastic Process" abbrv="">precancerous lesions</z:e> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> appears to be safe and showing promising efficacy </plain></SENT>
<SENT sid="14" pm="."><plain>Further clinical studies are required to establish the use of HPPH-<z:chebi fb="7" ids="53228">PDT</z:chebi> </plain></SENT>
</text></document>